EUCTR2013-002016-27-Outside-EU/EEA进行中(未招募)不适用
Open-label evaluation of the pharmacokinetic profile, safety, and efficacy of tapentadol oral solution for the treatment of post-surgical pain in children and adolescents aged from 2 years to less than 18 years.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 59
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A maximum body weight of 85.0 kg.
- •A minimum body weight of 10 kg for participants aged 2 years to less than 3 years old.
- •If female and post-menarchal, or 12 years or older, the subject has a negative urine pregnancy test within 24 hours before surgery.
- •Having completed either dental surgery or tonsillectomy with or without adenoidectomy surgery (age group: 6 to less than 18 years of age).
- •Having completed ear, nose, or throat surgery (including but not limited to tonsillectomy (age group: 2 to less than 3 years of age).
- •Participant aged 6 to less than 18 years has a post-operative pain intensity score greater than or equal to 4 on the Color Analog Scale (CAS) as a result of the surgical procedure or the participant has a pain level that the usual standard of care following the surgical procedure (which reliably produces moderate to severe pain) requires opioid treatment.
- •Participant aged 2 years to less than 6 years has a pain level following a surgical procedure that reliably produces moderate to severe pain, for which the usual standard of care requires opioid treatment.
- •Participant is alert, orientated, and able to follow commands and complete the post-operative required procedures.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 59
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of brain injury.
- •Clinically relevant abnormal ECG.
- •Clinically unstable vital signs and/or a saturation of oxygen saturation (SpO2) less than 93%. During surgery SpO2 may decrease <93%.
- •Clinically relevant abnormal values for clinical chemistry, hematology, or urinalysis at enrollment.
- •Body temperature above 38.5°C within 48 hours prior to dosing.
- •Positive drugs of abuse test result.
研究者
相似试验
进行中(未招募)
不适用
Pharmacokinetics and Tolerability Study of Tapentadol for Postsurgical Pain in Children and AdolescentsPainMedDRA version: 14.1Level: PTClassification code 10033371Term: PainSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2010-020380-20-Outside-EU/EEAJanssen Research & Development, L.L.C.40
进行中(未招募)
1 期
Pharmacokinetics and Tolerability Study of Tapentadol for Postsurgical Pain in Children and AdolescentsEUCTR2010-020380-20-ESJanssen Research & Development, L.L.C.44
进行中(未招募)
1 期
A clinical trial to find out how much tapentadol is in the blood of children who take tapentadol every 4 hours to treat short-term paiEUCTR2019-000205-77-PLGrünenthal GmbH15
已完成
不适用
An open-label study to assess the pharmacokinetics and safety/tolerability of pulsatile intra-vaginal delivery of a single dose of oxybutynin in healthy femalesNL-OMON51105iGalli BV8
已完成
2 期
Pharmacokinetics and Safety Study of Tapentadol for Postsurgical Pain in Children and AdolescentsPain, PostoperativePostoperative PainNCT01134536Janssen Research & Development, LLC45
